Skip to main content

Advertisement

Table 3 Cost effectiveness of UMEC/VI compared with tiotropium

From: Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK

Scenario Incremental QALYs Incremental costs ICER
Base case 0.18 £372.29 £2087.60
UMEC/VI price = tiotropium + 10 % 0.18 £687.81 £3856.87
UMEC/VI price = tiotropium + indacaterol 0.18 £3128.15 £17,540.98
Scenario A 0.01 −£0.89 Dominant
Scenario B 0.04 £22.69 £567.04
Scenario C 0.01 −£3.67 Dominant
  1. ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, UMEC/VI umeclidinium bromide-vilanterol